Description

Waters Corporation: The $520 Million Acquisition Signal Investors Need!

Waters Corporation reported its first quarter of fiscal year 2026 results following the recent acquisition of the Biosciences and Diagnostic Solutions businesses from Becton, Dickinson and Company (BD). The quarter marked a notable milestone as the combined company posted total revenues of $1.267 billion, with $747 million generated organically and $520 million attributed to the newly acquired segments since the acquisition’s closing on February 9, 2026. Organic revenue grew by 13% as reported and 11% on a constant currency basis, outperforming prior guidance by approximately 200 basis points. The acquired businesses contributed revenue growth estimated at 7% on a reported basis during Waters Corporation’s period of ownership, with the Biosciences segment growing 7% and Diagnostic Solutions growing 8%. Waters Corporation’s legacy Analytical Sciences Division delivered 12% constant currency growth, driven by broad-based strength across instruments, chemistry, and service lines, notably within the pharmaceutical, academic, government, and industrial sectors.